Methods for treating diabetic kidney disease and glomerular disease
AssigneeNephris SrL
InventorsPaolo FIORINA, Francesca D'ADDIO
Life of this patent
Estimating the term…
Abstract
Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1. Monoclonal anti-NBL1 antibodies are also provided.
Claims61
A method for delaying onset or progression of kidney damage in a subject who has type 1 diabetes or type 2 diabetes or a glomerular disease, the method comprising:
- administering to the subject an effective amount of an agent capable of inhibiting NBL1 activity.
The method of any one of claims 4-17, wherein the antibody or antigen binding fragment has a binding affinity (KD) for human NBL1 of less than 100 nM.
A method of treating diabetic kidney disease (DKD) or a glomerular disease in a subject who has type 1 or type 2 diabetes or a glomerular disease, the method comprising:
- administering to the subject an effective amount of an agent capable of inhibiting NBL1 activity.
An antibody or antigen binding fragment, wherein the antibody is capable of binding to NBL1 and inhibiting NBL1-induced toxicity of human podocytes.
Dependencies are inferred from the claim text.